Drug Trial Radar · NCT03590600
A Single Ascending Dose Study of BTZ043
Last checked: Nov 19, 2026Latest source record: Mar 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 7, 2018
Primary completion
Aug 14, 2018
Study completion Mar 5, 2019
Sponsor
- Lead sponsor
- Michael HoelscherAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- German Center for Infection Research; German Federal Ministry of Education and Research; Hans Knöll Institute (HKI)
- First posted
- Jul 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics of single doses of BTZ043 in healthy adult volunteers. The study is conducted at a study centre in Germany. Up to 50 male and female participants will be included in this study in up to 5 cohorts; each cohort will consist of 10 subjects: in each cohort 8 subjects will be assigned to BTZ-043 and 2 to placebo. The doses tested will be: 125mg, 250mg, 500mg, 1000mg and 2000mg. Safety will be assessed via regular vital sign measurement, 12-lead ECG parameters, physical examination and safety laboratory assessments. Subjects will be hospitalized from Day -1 until discharge in the morning of Day 3. After completion of all Day 3 assessments of a cohort, blinded safety data will be reviewed and the next dose increment will be decided by the Trial Steering Committee (TSC).
Conditions
- Tuberculosis
- Tuberculosis, Pulmonary
- Bacterial Infections
- Lung Diseases
- Mycobacterium Infections
Interventions
BTZ-043Drug
Powder and solvent for oral suspension
PlaceboDrug
Matching placebo: powder and solvent for oral suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events concerning ECG as assessed by CTCAE v4.03 (Common Terminology Criteria for Adverse Events)Time frame: 0.5 hours to 12.0 hours post-dosing
- Number of participants with treatment-related adverse events concerning safety laboratory as assessed by CTCAE v4.03Time frame: 24 hours to 26 hours post-dosing
- Number of participants with treatment-related adverse events concerning vital signs as assessed by CTCAE v4.03Time frame: 0.25 hours to 48 hours post-dosing
- Number of participants with treatment-related adverse events concerning clinical observations as assessed by CTCAE v4.03Time frame: 4 hours to 48 hours post-dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nuvisan
Neu-Ulm, Bavaria, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.